小柯机器人

科学家开发出可诱导保护性免疫的新冠病毒靶向疫苗
2020-08-02 23:45

四川大学Xiawei Wei等研究人员合作研发出可诱导保护性免疫的SARS-CoV-2 S蛋白RBD靶向疫苗。这一研究成果于2020年7月29日在线发表在《自然》上。

据研究人员介绍,新型冠状病毒SARS-CoV-2引起呼吸道疾病,称为COVID-19,并导致大流行。目前迫切需要一种有效的预防这种病毒的疫苗。作为感染过程中最关键的步骤,SARS-CoV-2使用其Spike蛋白受体结合域(S-RBD)与宿主细胞受体血管紧张素转换酶2(ACE2)结合。
 
研究人员表明,包含S-RBD残基319-545的重组疫苗可在单剂注射后7或14天时,在免疫的小鼠、兔和非人灵长类动物(猕猴)中诱导有效的功能性抗体反应。免疫动物的血清在体外阻断了RBD与细胞表面表达的ACE2的结合,并中和了SARS-CoV-2假病毒和活SARS-CoV-2的感染。重要的是,该疫苗还为非人类灵长类动物提供了体内SARS-CoV-2攻击的保护。在COVID-19患者的血清中也发现了升高的RBD特异性抗体。几种免疫途径和CD4 T淋巴细胞与疫苗抗体反应的诱导有关。
 
这些发现突出了RBD结构域在SARS-CoV-2疫苗设计中的重要性,并为通过诱导针对RBD结构域的抗体的保护性疫苗开发提供了依据。
 
附:英文原文

Title: A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Author: Jingyun Yang, Wei Wang, Zimin Chen, Shuaiyao Lu, Fanli Yang, Zhenfei Bi, Linlin Bao, Fei Mo, Xue Li, Yong Huang, Weiqi Hong, Yun Yang, Yuan Zhao, Fei Ye, Sheng Lin, Wei Deng, Hua Chen, Hong Lei, Ziqi Zhang, Min Luo, Hong Gao, Yue Zheng, Yanqiu Gong, Xiaohua Jiang, Yanfeng Xu, Qi Lv, Dan Li, Manni Wang, Fengdi Li, Shunyi Wang, Guanpeng Wang, Pin Yu, Yajin Qu, Li Yang, Hongxin Deng, Aiping Tong, Jiong Li, Zhenling Wang, Jinliang Yang, Guobo Shen, Zhiwei Zhao, Yuhua Li, Jingwen Luo, Hongqi Liu, Wenhai Yu, Mengli Yang, Jingwen Xu, Junbin Wang, Haiyan Li, Haixuan Wang, Dexuan Kuang, Panpan Lin, Zhengtao Hu, Wei Guo, Wei Cheng, Yanlin He, Xiangrong Song, Chong Chen, Zhihong Xue, Shaohua Yao, Lu Chen, Xuelei Ma, Siyuan Chen, Maling Gou, Weijin Huang, Youchun Wang, Changfa Fan, Zhixin Tian, Ming Shi, Fu-Sheng Wang, Lunzhi Dai, Min Wu, Gen Li, Guangyu Wang, Yong Peng

Issue&Volume: 2020-07-29

Abstract: The novel Coronavirus SARS-CoV-2 causes a respiratory illness called COVID-19 leading to a pandemic. An effective preventive vaccine against this virus is urgently needed. As the most critical step during infection, SARS-CoV-2 uses its Spike protein receptor-binding domain (S-RBD) to engage with the host cell receptor angiotensin-converting enzyme 2 (ACE2)1,2. Here we showed that a recombinant vaccine comprising residues 319-545 of the S-RBD could induce a potent functional antibody response in the immunized mice, rabbits and non-human primates (Macaca mulatta) as early as 7 or 14 days after a single dose injection. The sera from the immunized animals blocked RBD binding to ACE2 expressed on the cell surface and neutralized the infection by SARS-CoV-2 pseudovirus and live SARS-CoV-2 in vitro. Importantly, the vaccination also provided protection in non-human primates from SARS-CoV-2 challenge in vivo. The elevated RBD-specific antibodies were also found in the sera from patients with COVID-19. Several immune pathways and CD4 T lymphocytes were implicated in the induction of the vaccine antibody response. Our finding highlights the importance of the RBD domain in the SARS-CoV-2 vaccine design and provides the rationale for the development of a protective vaccine through the induction of antibody against the RBD domain.

DOI: 10.1038/s41586-020-2599-8

Source: https://www.nature.com/articles/s41586-020-2599-8

Nature:《自然》,创刊于1869年。隶属于施普林格·自然出版集团,最新IF:69.504
官方网址:http://www.nature.com/
投稿链接:http://www.nature.com/authors/submit_manuscript.html


本期文章:《自然》:Online/在线发表

分享到:

0